Skip to Content

'
Luhua (Michael) Wang, M.D.

Present Title & Affiliation

Primary Appointment

Tenured Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Division of Cancer Medicine, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Mantle Cell Lymphoma Program of Excellence, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Myeloma Tissue Bank, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 429
Houston, TX 77030
Room Number: Faculty Center, FC6.2038
Phone: (713) 792-2860
Fax: (713) 563-5067
Email: miwang@mdanderson.org

Education & Training

Degree-Granting Education

1988 Beijing Medical University, Beijing, China, MS, Physiology
1985 Shandong Medical University, Jinan, China, MD, Medicine

Postgraduate Training

7/1999-6/2002 Medical Oncology/Hematology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1997-6/1998 Chief Medical Resident, Yale-Norwalk Hospital, Norwalk, CT
7/1995-6/1997 Residency, Yale-Norwalk Hospital, Norwalk, CT
6/1994-6/1995 Internship, Dept. of Internal Medicine, The University of Michigan Hospitals, Ann Arbor, MI
2/1991-6/1994 Visiting Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD
10/1988-1/1991 Visiting Fellow (Recipient of Fogarty International Fellowship Award), National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD

Board Certifications

1/2014 American Board of Internal Medicine, Medical Oncology
1/1998 American Board of Internal Medicine, Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-9/2009
Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2001-6/2002
Instructor, Dept. of Internal Medicine, University of Texas Medical School, Houston, TX, 7/1998-6/1999
Chief Medical Resident, Yale-Norwalk Hospital, Norwalk, CT, 7/1997-6/1998
Visiting Associate, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, 2/1991-6/1994

Other Appointments/Responsibilities

Medical Liaison in Myeloma, The University of Texas MD Anderson Cancer Center - Orlando, Orlando, FL, 11/2002-12/2007

Institutional Committee Activities

Member, China Steering Committee, Extramural Programs, M.D. Anderson Cancer Center, 9/2005-present
Member, Clinical Research Committee M.D. Anderson Cancer Center, 7/2005-7/2006
Member, Clinical and Translational Research Steering Committee M.D. Anderson Cancer Center, 2/2005-6/2006
Member, NCI Sponsored Clinical Trial Faculty M.D. Anderson Cancer Center, 11/2002-present
Member, Internal Advisory Committee to Complementary Integrative Medicine M.D. Anderson Cancer Center, 1/2002-1/2004

Honors and Awards

2011 "Top Doctor", Castle Cannolly Medical Ltd
2011 Best Doctor, U.S. News & World Report
2010 "America's Top Oncologist,", Consumers' Research Council of America
2007 "America's Top Oncologist,", Consumers' Research Council of America
1997-1998 Recognition Award for Outstanding Service as Chief Resident in Medicine, Norwalk Hospital, Norwalk, CT
1988-1990 Fogarty International Fellowship Award, National Institutes of Health, Bethesda, MD

Selected Publications

Peer-Reviewed Original Research Articles

1. Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol 167(1):3-18, 10/2014. e-Pub 6/28/2014. PMID: 24974852.
2. Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget 5(17):7368-80, 9/2014. PMID: 25228589.
3. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/18/2014. PMID: 24943107.
4. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst 106(9), 9/2014. e-Pub 9/2014. PMID: 25214559.
5. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol. e-Pub 8/25/2014. PMID: 25154820.
6. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 124(7):1038-46, 8/14/2014. e-Pub 6/11/2014. PMID: 24920586.
7. Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B. Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. Clin Lymphoma Myeloma Leuk. e-Pub 7/15/2014. PMID: 25108680.
8. Desai M, Newberry K, Ou Z, Wang M, Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol 5(3):91-101, 6/2014. PMCID: PMC4031905.
9. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 5/9/2014. PMCID: PMC4038108.
10. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
11. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, Bihl M, Swerdlow SH, Rosenwald A, Ott G, Said J, Dunphy CH, Bueso-Ramos CE, Lin P, Wang M, Miranda RN, Tzankov A, Medeiros LJ, Young KH. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol 44(1):110-21, 1/2013. e-Pub 8/31/2012. PMCID: PMC3640316.
12. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41(1):67-78, 1/2013. e-Pub 9/14/2012. PMID: 22986101.
13. Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 6:92, 2013. e-Pub 12/10/2013. PMCID: PMC3878866.
14. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 2012. PMID: 22833546.
15. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 2012. PMID: 21887685.
16. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 2012. PMID: 22015451.
17. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 2012. PMID: 22555973.
18. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158(6):739-48, 2012. PMID: 22845873.
19. Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, Kim ES, Heymach JV, Wang M, Girard L, Minna J, Roth JA, Swisher SG, Fang B. Antitumor Activity of a Novel STAT3 Inhibitor and Redox Modulator in Non-Small Cell Lung CancerCells. Biochem Pharmacol 83(10):1456-64, 2012. PMID: 22387047.
20. Fu W, Delasalle K, Wang J, Song S, Hou J, Alexanian R, Wang M. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol 35(6):562-5, 2012. PMID: 21694573.
21. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-118, 2012. PMID: 22024108.
22. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 2012. PMID: 22294726.
23. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363– 368, 2012. PMID: 22000823.
24. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber D, Wang M, Orlowski R, Thomas S, Shah J, Qureshi S, Dinh Y, Popat U, Anderlini P, Hosing C, Giralt S, Champlin R, Qazilbash M. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 2012. PMID: 21780997.
25. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab in patients with relapsed and refractory mantle cell lymphoma: a phase I/II clinical trial. Lancet Oncology 13(7):716-23, 2012. PMID: 22677155.
26. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 2012. PMID: 22231283.
27. Zhang L, Yang J, Qian J, Li H, Romaguera J, Kwak L, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 2012. PMID: 22968454.
28. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 2012. PMID: 22932796.
29. Wang H, Chen Y, Li F, Delasalle K, Wang J, Alexanian R, Kwak L, Rustveld L, Du XL, Wang M. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Cancer 118(15):3793-800, 2012. PMID: 22139816.
30. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159(2):243-6, 2012. PMID: 22924544.
31. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang M, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 2011. PMID: 21477075.
32. Hunsucker S, Valeria Magarotto V, Kornblau S, Wang M, Weber DM, Thomas SK, Shah J, Voorhees P, Xie H,Cornfeld M,Nemeth JA, Orlowski R. Blockade of Interleukin-6 Signaling with Siltuximab Enhances Melphalan Cytotoxicity in Preclinical Models of Multiple Myeloma. Br J Haematol 152(5):579-92, 2011. PMID: 21241278.
33. Bjorklund C, Ma W, Wang ZQ, Davis RE, Kuhn D, Kornblau S, Wang M, Shah J, Orlowski R. Evidence of a Role for Activation of Wnt/β-catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. J Biol Chem 286(13):11009-11020, 2011. PMID: 21189262.
34. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 2011. PMID: 21844567.
35. Wen J, Feng Y, Bjorklund C, Wang M, Orlowski RZ, Shi Z, Liao B, OHare J, Zu Y, Schally A, Chang C. Luteinizing hormone-releasing hormone (LHRH)-I antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-58, 2011. PMID: 21062912.
36. Tan CH, Wang M, Fu WJ, Vikram R. Nodular extramedullary multiple myeloma involvement of the liver presenting as hypervascular lesions on CT. Ann Acad Med Singapore. Ann Acad Med Singapore 40(7):329-3, 2011. PMID: 21870026.
37. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 2011. PMID: 21554263.
38. Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52., 2011. PMID: 21813633.
39. Harousseau JL, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95(10):1738-44, 2010. PMID: 20460639.
40. Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 45(3):498-504, 2010. PMID: 19633690.
41. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 2010. PMID: 20805315.
42. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 2010. PMID: 21057542.
43. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35(3):380-6, 2010. PMID: 21047686.
44. Ross WA, Egwim CI, Wallace MJ, Wang M, Madoff DC, Lee JH. Outcomes in Lymphoma Patients with Obstructive Jaundice: A Cancer Center Experience. Digestive Diseases and Sciences 55(11):3271-7, 2010. PMID: 20632106.
45. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 2010. PMID: 20735402.
46. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 2010. PMID: 20851072.
47. Wang M, Delasalle K, Giralt S, Alexanian R. Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide– dexamethasone (BLD). Hematology 15(2):70 - 73, 2010. PMID: 20423566.
48. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 2010. PMID: 20528872.
49. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15(7):812-816, 2009. PMID: 19539212.
50. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Yi Q. Cyclin D1 as a universally-expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23(7):1320-1328, 2009. PMID: 19225534.
51. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 2009. PMID: 19710503.
52. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma Cell Line-Derived, Pooled Heat Shock Proteins as a Broad Vaccine for Immunotherapy of Multiple Myeloma. Blood 114(18):3880-9, 2009. PMID: 19654406.
53. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. J Clin Oncol 27(3), 2009. PMID: 19770379.
54. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84(9):553-9, 2009. PMID: 19565649.
55. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14(7):2154-2160, 2008. PMID: 18381957.
56. Qazilbash M, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S,. Arsenic Trioxide with Ascorbic Acid and High-Dose. American Society for Blood and Marrow Transplantation 14(12):1401-1407, 2008. PMID: 19041063.
57. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a Phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. PMID: 19041063.
58. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22(1):179-85, 2008. PMID: 17898787.
59. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status and survival in a large population-based cohort of elderly patients with non-Hodgkin's Lymphoma. Cancer 113(11):3231-3241, 2008. PMID: 18937267.
60. Zhou Y, Wang H, Fang W, Romaguera J, Zhang Y, Delasalle K, Kwak L, Yi Q, Du X, Wang M. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113(4):791-798, 2008. PMID: 18615506.
61. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12):4445-4451, 2008. PMID: 18799726.
62. Wang M, Fayad L, Hagemeister F, McLaughlin P, Rodriguez A, Cabanillas F, Younes A, Neelapu S, Goy A, Zhou Y, Wang J, Beasley V, Kwak L, Kantarjian H, Romaguera J. Phase II trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed/refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-2741, 2008. PMID: 18973182.
63. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 9/2007. e-Pub 7/2007. PMID: 17697969.
64. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-94, 9/2007. e-Pub 5/2007. PMCID: PMC1975842.
65. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 9/2007. PMID: 17785206.
66. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 6/2007. e-Pub 2/2007. PMID: 17317853.
67. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 2007. PMID: 17644731.
68. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. PMID: 17262062.
69. Wang M, Giralt S, Delasalle K, Alexanian R. Bortezomib in combination with Thalidomide-Dexamethasone for previously untreated myeloma. Haematology 12(3):235-239, 2007. PMID: 17558699.
70. Rohatgi N, Du XL, Coker AL, Moye L, Wang M, Fang S. Chemotherapy and survival for patients with multiple myeloma: Findings from a large nationwide and population-based cohort. Am J Clin Oncol 30(5):540-548, 2007. PMID: 17921717.
71. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy Jr J, Epstein J, Kwak L, Yi Q. Dickkopf-1 (DKK1) is a widely expresed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-1594, 2007. PMID: 17515399.
72. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Knight RD. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133-42, 2007. PMID: 18032763.
73. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4):502-5, 2007. PMID: 17608763.
74. Dang NH, Fayad L, McLaughlin P, Romaguera JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker P, Wang M, Rodriguez MA, Ton A, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Br J Hem 138:502-505, 2007. PMID: 17608763.
75. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 2006. PMID: 17054068.
76. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17)(17):2976-81, 2006. PMID: 17008093.
77. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4)(4):295-307, 2006. PMID: 17045207.
78. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal B, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 93(1):70-80, 2005. PMID: 15970928.
79. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels B, Smith TL, Cabanillas F. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate/cytarabine. J Clin Oncol 23(28)(28):7013-23, 2005. PMID: 16145068.
80. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4)(4):667-75, 2005. PMID: 15613697.
81. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 79(3):194-7, 2005. PMID: 15981221.
82. Li Z, Ibrahim NK, Wathen JK, Wang M, Menchu R, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. PMID: 15378497.
83. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 2004. PMID: 15353540.
84. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Sem in Hem 40(4):3-7, 2003. PMID: 15015890.
85. Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian M, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35(31):10194-10202, 1996. PMID: 8756484.
86. Kusui T, Hellmich MR, Wang LH, Evans RL, Benya RV, Battey JF, Jensen RT. Characterization of gastrin-releasing peptide receptor expressed in Sf9 insect cells by baculovirus. Biochemistry 34(25):8061-75, 1995.
87. Benya, RV, Wada, E, Battey, JE, Fathi, Z, Wang, LH, Mantey, SA, Coy, DH, Jensen, RT. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: Analysis of binding, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharm 42(2):8061-75, 1994.
88. Wang LH, Mantey SA, Lin JT, Frucht H, Jensen RT. Ligand binding, internalization, degradation and regulation by guanine nucleotides of bombesin receptor subtypes: A comparative study. Biochim Biophys Acta 1175((2)):232-42, 1993. PMID: 8380344.
89. Wang LH, Battey JF, Wada E, Lin JT, Mantey S, Coy DH, Jensen RT. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Calcium and phosphoinositides. Biochem J 286(Pt2):641-8, 1992. PMID: 1326946.
90. Benya RV, Wada E, Battey JF, Fathi Z, Wang LH, Mantey SA, Coy DH, Jensen RT. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: Analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors. Mol Pharmacol 42((6)):1058-68, 1992. PMID: 1336112.
91. Coy DH, Jiang NY, Kim SH, Moreau JP, Lin JT, Frucht H, Qian JM, Wang LH, Jensen RT. Covalently-cyclized agonist and antagonist analogues of bombesin and related peptides. J Biol Chem 266(25):16441-7, 1991.
92. Rowley WH, Sato S, Huang SC, Collado-Escobar DM, Beaven MA, Wang LH, Martinez J, Gardner JD, Jensen RT. Cholecystokinin-induced formation of inositol phosphates in pancreatic acini. Am J Physiol 259:G655-65, 1990. PMID: 1699431.
93. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, Frucht H, Haffar BM, Jensen RT. Des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists. J Biol Chem 265(26):15695-703, 1990. PMID: 1697594.
94. Wang LH, Coy DH, Taylor JE, Jiang NY, Kim SH, Moreau JP, Huang SC, Mantey SA, Frucht H, Jensen RT. Desmethionine alkylamide bombesin analogues: A new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry 29(3):616-22, 1990. PMID: 1692477.
95. von Schrenck T, Wang LH, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol 259:G468-73, 1990. PMID: 2169207.
96. Coy D, Wang LH, Jiang NY, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol 190:31-8, 1990. PMID: 1963850.
97. Sawyer TK, Jensen RT, Moran TH, Wang LH, Coy DH, Staples DG, DeVaux AE, Bradford VS. Structure activity relationships of cholecytokinin: Tyr[SO3H]: Substitutions Peptides. Chemistry, Structure and Biology:143-5, 1990.
98. Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Gardner JD, Jensen RT. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem 264(25):14691-7, 1989. PMID: 2475489.

Invited Articles

1. Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang M, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol 43(4):467-80, 1/2012. PMID: 22221705.
2. Alexanian R, Delasalle K, Wang M, Thomas S and Weber DM. Curability of Multiple Myeloma. Bone Marrow Research 2012;2012:916479. doi: 10.1155/2012/916479, 2012. PMID: 22675638.
3. Wang M. Comparative Mechanisms of Action of Proteasome Inhibitors. Oncology Supplement(2):1-6, 2011.
4. Zhou Y, Garcia MK, Chang DZ, Chiang J, Lu J, Yi Q, Romaguera J, Delasalle K, Alexanian A, Guo Y, Forman A, Fang W, Wang M. Multiple myeloma, painful neuropathy, acupuncture? Am J Clin Onc 32(3):319-325, 2009. PMID: 19887992.
5. Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 11(1):87-95, 2/2007. PMID: 17441400.
6. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma. Am J Hem 83(2):144-149, 2007. PMID: 17722077.
7. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 6(7):983-91, 7/2006. PMID: 16831071.
8. Wang M, Nguyen C, Alexanian A. Effective new agents for multiple myeloma. Case Studies in Myeloma, Physicians' Education Resource. 2(2):1-7, 2006.
9. Wang M, Younes A. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma 3:173-4, 2002. PMID: 12521395.

Editorials

1. Ke X, Wang Y, Yang Y, Wang M. Multiple Myeloma: Past, Present and Future. J Exp Hematol 16(2):231-239, 2008. PMID: 18426640.

Abstracts

1. Niesvizky R, Bensinger W, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE,Kunkel LA,Vallone M, Wong A, Wang M. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. 16th Congress of the European Hematology Association (EHA), 2011.
2. Wang M, Stewart AK, Kaufman JL, Jakubowiak A, Jagannath S, Kukreti V, Mcdonagh K, Alsina M, Bahlis N, Belch A, Reu FJ, Gabrail N, Matous JV, Vesole DH, Orlowski RZ, Kunkel LA, Le MH, Lee P, Rosen PJ, Sebag M, Vij R, Multiple myeloma research consortium (MMRC). Carfilzomib (CFZ) produces a high single-agent response rate with minimal neuropathy even in relapsed multiple myeloma (MM) patients (Pts) with high-risk disease. 13th International Myeloma Workshop(IMW) (#P-211), 2011.
3. Wang M, Garcia K, Zhou Y, You B, Guo Y, Forman A, Chiang J, Orlowski R, Shah J, Alexanian R, Thomas S, Qazilbash M, Badilo M, Chen Y, Delasalle K, Green V, Romaguera J, Cohen L. Electroacupuncture is an effective therapeutic modality for bortezomib- or thalidomide-induced peripheral neuropathy in patients with multiple myeloma: A Pilot Study. 13th International Myeloma Workshop(IMW) (#P-367), 2011.
4. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
5. Lu G, Li S, Alseraye F, Muddasani R, Abruzzo L, Wang M, You MJ, Medeiros LJ. Plasma Cell Myeloma with IGHV Deletion: A Subset of Patients with Poor Prognosis. United States and Canadian Academy of Pathology, 2011.
6. Wang M, Bensinger M, Martin T, Alsina M, Siegel DS, Gabrail NY, Hari P, Singhal S, Vescio RA, Assouline SE, Kunkel LA, Vallone M, Wong A, Niesvizk R. PX-171-006: a Phase (Ph) 2 Multicenter Dose Expansion Study of Carfilzomib (CFZ), Lenalidomide (LEN), and Low-dose Dexamethasone (loDex) in Relapsed and/or Refractory Multiple Myeloma (R/R MM). 2011 ASCO Annual Meeting (#8025), 2011.
7. Wang M, Wang H, Chen Y, Li F, Delasalle K, Alexanian R, Kwak L, Rustveld L, Du X. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: A large population-based study. Haematologica 96(s2):402 (#0966), 2011.
8. Wang M, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A. The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. Blood (ASH Annual Meeting Abstract) 118 (#442), 2011.
9. Kaufman JL, Vesole DH, Stewart A, Jakubowiak AJ, Jagannath S, Kukreti V, Mcdonagh KT, Alsina M, Reu FJ, Orlowski RZ, Kunkel L, Le MH, Vij R, Wang M. Updated Results for Bortezomib (BTZ)-naïve Patients (Pts) Enrolled in PX-171-004, an Ongoing Open-label, Phase (Ph) 2 Study of Carfilzomib (CFZ), in Relapsed Multiple Myeloma. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
10. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, Weber D. Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting) 116:1948, 11/2010.
11. Wang M, Niesvizky R, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 1b Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). 2010 Lymphoma / Myeloma meeting in NYC, 2010.
12. Martin T, Niesvizky R, Wang M, Orlowski R, Alsina M, Singhal S, Gabrail N, Vallone M, Bui L, Kauffman M, Bensinger W. Phase 2 Multicenter Dose Expansion Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM). 2010 Lymphoma / Myeloma meeting in NYC, 2010.
13. Wang M, Bensinger W, Orlowski R, Alsina M, Martin T, Singhal S, Gabrail N, Vallone M, Kauffman M, Niesvizky R,. PX-171-006, a phase Ib dose-escalation study of carfilzomib+lenalidomide+low-dose dexamethsaone in relapsed and/or refractory multiple myeloma. 15th Congress of the European Hematology Association, 2010.
14. Hunsucker SA, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, and Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 sensitized plasma cell dyscrasias to the effects of melphalan in association with suppression of signaling through protein kinase B/Akt. Blood (ASH Annual Meeting Abstract) 114 (#1836), 12/2009.
15. Yang J, Cao Y, Zheng Y, Hong S, Li H, Qian J, Matthews JA, Wang M, Kwak LW, and Yi Q. Constitutive Activation of p38 MAPK in Myeloma Cells Contributes to Myeloma-Induced Osteolytic Bone Lesions. Blood (ASH Annual Meeting Abstracts) 114:740, 11/2009.
16. Bjorklund CC, Kuhn DJ, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Activation of the wnt/β-catenin pathway mediates lenalidomide resistance in multiple myeloma. 51st ASH Annual Meeting 114:111, 2009.
17. Kuhn DJ, Bjorklund CC, Magarotto V, Matthews JA, Wang M, Baladandayuthapani V, and Orlowski RZ. Bortezomib resistance is mediated by increased signaling through the insulin-like growth factor-1akt axis. 51st ASH Annual Meeting, 2009.
18. Stadtmauer EA, Weber DM, Wang M, Nieszvizky R, Belch A, Prince HM, J. F. Miguel JF, Facon T, Yu Z, Knight RD, Dimopoulos MA. The quality of response to lenalidomide plus dexamethasone is associated with clinical outcomes in patients with relapsed or refractory multiple myeloma. 2009 ASCO Annual Meeting J Clin Oncol 27(15s) (#8594), 2009.
19. Wang M, Zhang L, Fayad L, Hagemeister F, Neelapu S, Samaniego F, Pro B, Miller S, Knight R, Zeldis J, Yi Q, Romaguera J. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a Phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(11) (#3058), 2008.
20. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Proc ASCO 25(18S):8030, 2007.
21. Wang M, Shi Y, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Romaguera J, Kwak L, Yi Q. A SCID-hu in vivo mouse model of human primary mantle cell lymphoma. Blood 110(11):691a, abstr 2337, 2007.
22. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R.. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 12(3):235-239, 2007. PMID: 17558699.
23. Wang M, Delasalle K, Thomas S, Qazilbash M, Giralt S, Weber D, Alexanian R. Early transplant is useful for older patients with multiple myeloma. Haematologica 92(6):189, (abstr PO-819), 2007.
24. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj M, Weber D. Effect of Lenalidomide/Dexamethasone in multiple myeloma despite Thal resistance. Haematologica 92(6):172, (abstr PO-662), 2007.
25. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide (Len) in combination with Rituximab demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL). Blood 110(11):755a, abstr 2562, 2007.
26. Wang M, Zhou Y, Wang H, Yi Q, Zhang Y, Alexanian R, Kwak L, Du X. Trend and geographic variations in the incidence of Waldenstrom's Macroglobulinemia in the United States over 17 years from 1988 to 2004. Blood 110(11):5174, 2007.
27. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Yu Z, Zeldis J, Olesnyckyj, Weber DM. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received thalidomide in relapsed or refractory multiple myeloma (MM). J Clin Oncol 24(185):7522, 2006.
28. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 108(11):123a, (abstr 403), 2006.
29. Wang M, Knight R, Dimopoulos M, Siegel D, Rajkumar SV, Facon T, Alexanian R, Yu Z, Zeldis J, Olesnyckyj, Weber D. Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood 108 (#3553), 2006.
30. Wang M, Oki Y, Pro B, Romaguera J, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 108(11):767a, (abstr 2714), 2006.

Book Chapters

1. Wang M, Zhang L, Ou Z, Sun L, Desai MV, Young KH, Champlin RE, Kwak LW, Romaguera JE. Mantle Cell Lymphoma. In: Hoffman’s Hematology (the sixth edition). In Press.
2. Avery TP, Shah ND, Fu W, Weber DM, Lu G, Lin P, Qazilbash M, Wang M. Multiple Myeloma and other plasma cell dyscrasias. In: M.D. Anderson Manual of Medical Oncology 2nd Edition. McGraw-Hill Companies, 245-282, 2011.
3. Thomas S, Wang M, Weber D. Abnormal serum protein electrophoresis. In: Decision Making in Medicine, An Algorithmic Approach. In: Woman's Health. Women's Health, 264-267, 2010.
4. Zhou Y, Alexanian R, Wang M. Targeted Therapy in Multiple Myeloma. In: Targeted Therapy in Cancer. Springer Science+Business Media: Totowa, NJ, 213-236, 2008.
5. Seymour G, Wang M, Weber D. Multiple myeloma and other plasma-cell dyscrasias. In: M.D. Anderson Manual of Medical Oncology. Ed(s) Kantarjian HM, Wolff RA, Koller CA. McGraw-Hill Companies, 175-195, 2006.
6. Jensen, RT, Wang, LH, Lin, JT, Benya, RV, Mroziski, JE, Jr, Coy, DH. Peptide-neuromedin B (NMB) receptor interactions: Comparison with gastrin-releasing peptide (GRP): GRP receptor interactions. In: Growth Factors, Peptides and Receptors. Plenum Publishing Co., 225-37, 1993.

Last updated: 10/22/2014